Community Based Treatment for (ComBaT) Glaucoma

Sponsor
University of Michigan (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06124521
Collaborator
National Institute on Minority Health and Health Disparities (NIMHD) (NIH)
60
1
1
36
1.7

Study Details

Study Description

Brief Summary

The purpose of this research is to evaluate if intervention and education can change the behavior of someone's willingness to see an eye care provider to prevent blindness and glaucoma. The researchers are investigating if adding additional resources improves participant access to care.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: ComBaT Glaucoma
N/A

Detailed Description

Outcome measures related to acceptability and feasibility are exploratory. They will not be registered or results reported.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Increasing Eye Care Utilization in Black Americans At High Risk For Glaucoma Using A Community-Engaged and Faith-Based Intervention
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2026
Anticipated Study Completion Date :
Nov 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Eye concern

Those with a diagnosis of glaucoma or glaucoma suspect (or other concerning eye disease, such as diabetic retinopathy or macular degeneration) will be invited to participate in the ComBaT Glaucoma.

Behavioral: ComBaT Glaucoma
ComBaT Glaucoma is a personalized counseling and education program about the participant's diagnosis and the importance of glaucoma follow-up care in maintaining vision.

Outcome Measures

Primary Outcome Measures

  1. Eye care utilization [Up to 14 months]

    Participants who have not seen an eye care provider for an initial clinical evaluation within 6 months of entering the program or a follow-up evaluation at 12 months will be considered underutilizers. Those who have received evaluation at 6 and 12 months will be considered normal utilizers.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Black or African American

  • Participated in the screening examination portion of the study

Exclusion Criteria:
  • Current eye pain (> 8 out of 10)

  • Sudden decrease in vision (within 1 week)

  • Double vision that doesn't stop when you blink and stops no matter what eye you cover (not blurred, but seeing 2 objects)

  • Pregnant women

  • Prisoners

  • Cognitive impairment- unable to give an ocular and social history

  • Moving outside of Michigan or driving distance to the church within 6 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Michigan Ann Arbor Michigan United States 48109

Sponsors and Collaborators

  • University of Michigan
  • National Institute on Minority Health and Health Disparities (NIMHD)

Investigators

  • Principal Investigator: Angela Elam, University of Michigan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Angela Elam, Assistant Professor of Ophthalmology and Visual Sciences, University of Michigan
ClinicalTrials.gov Identifier:
NCT06124521
Other Study ID Numbers:
  • HUM00207876
  • K23MD016430-03
First Posted:
Nov 9, 2023
Last Update Posted:
Nov 9, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Angela Elam, Assistant Professor of Ophthalmology and Visual Sciences, University of Michigan
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 9, 2023